Stock Market

Wockhardt shares climb 2% after USFDA makes nil observation

   Download Android App    Share in      FullScreen   CheckVideos

NEW DELHI: Shares of pharmaceutical firm Wockhardt climbed over 2 per cent in early trade on Monday. Shares of the company got tractions after it said that the USFDA's inspection of its Bioequivalence centre in Aurangabad, Maharashtra yielded no observations. In a regulatory filing, the company said no observations were made after the US drug regulator inspected its Bioequivalence centre during which Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited. "At the end of inspection, there was nil observation (i.e.

zero 483 observation), signifying that best practices were followed, in compliance to applicable regulations.

This outcome would lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will be done in the said Centre," the company said. Shares of the company traded 1 per cent up at Rs 453.75 apiece around 10:15 am on BSE.




Unlimited Portal Access + Monthly Magazine - 12 issues-Publication from Jan 2021

Buy Our Merchandise (Peace Series)

 

Contribute US to Start Broadcasting


It's Voluntary! Take care of your Family, Friends and People around You First and later think about us. Its Fine if you dont wish to contribute and if you wish to contribute then think about the Homeless first and Feed them. We can survive with your wishes too :-). You can Buy our Merchandise too which are of the finest quality.

Debit/Credit/UPI

UPI/Debit/Credit

Paytm

STRIPE

Details
Category: Stock Market


21